ARGX argenx BVBA: רווח נקי למניה ב-12 החודשים האחרונים

Cash flow stability for argenx SE (ARGX) is increasing due to the implementation of immunological solutions with inelastic demand. Its status as a leading innovator strengthens physician confidence and the asset's attractiveness to investors. The business relies on high-margin rare disease niches, driving a sharp surge in revenues. This chart of the annual percentage growth of EPS TTM confirms this trend, and the parameter has stabilized at 29.70.
argenx BVBA - פילוחים אנליטיים ומדדי מפתח (ARGX)

The full capacity utilization of partners producing immunological drugs directly determines the profit dynamics of argenx SE. The history of EPS YoY (TTM) percentage changes reflects the growth rate of net income per share over a rolling year. This metric is calculated as the difference between current and previous EPS values, measuring the real efficiency of capital management. A positive trend confirms the scalability of the business and the resilience of the asset's fundamental value.